Skip to main content
BAYRY
OTC Life Sciences

Judge Approves $7.25B Roundup Settlement, Clearing Bayer's Biggest Legal Overhang

Tom Rudovsky · Reported by Seeking Alpha
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$15.01
Mkt Cap
$58.899B
52W Low
$7.65
52W High
$15.98
52W Position info
96% above low
Off High info
6.1% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

BAYRY sits 96% above its 52-week low of $7.65 on elevated volume (2.2× avg).

Summary

A Missouri circuit judge approved Bayer's $7.25B settlement of Roundup cancer claims, calling it fair, reasonable and adequate. The deal, first announced in February, resolves nearly all current and future U.S. Roundup claims and pays individuals $10K to $165K based on cancer severity, age, and whether exposure was occupational or residential. This is the legal overhang that has dogged Bayer since the 2018 Monsanto acquisition, when shares fell 80% in the years that followed. The company already won its Supreme Court case on the government-approved warning label, which undercut a central claim in many suits, so court approval removes the last major procedural hurdle. BAYZF is the same Bayer AG security on a different OTC line. Watch for the pace of remaining opt-outs and any appeals, which would determine whether the $7.25B cap actually holds.

At the time of this announcement, BAYRY was trading at $15.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $58.9B. The 52-week trading range was $7.65 to $15.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.


Price Chart

Share this article

Copied!

BAYRY - Latest Insights

BAYRY
Nov 09, 2026, 9:08 PM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $15.91
Real-time Price: $15.01 info
Change: -$0.900 (-6%) info
Market Cap: $58.899B info